Opening of Bids - Byer's Softball Complex Improvements Proj No 123-071 - Premium Concrete Services

Home Browse Search

All collections are completed by the specimens being sealed and labeled, the CCF being properly executed, and the specimens and the CCF being sealed in a plastic bag for shipment to the laboratory. 5. Drug Testing Laboratory Compliance. " PHMSA's Substance Abuse Program Comprehensive Audit and Inspection Protocol Form, Specimen Collection Sites, Form No.: 3.1.7 (Revision 2)" provides a separate inspection protocol for Specimen Collection Sites. The Company provides this protocol to correspond with the detail found in the PHMSA Inspection Form. As previously stated, the Company will ensure that all DOT drug tests comply with Part 40 requirements. Laboratory. The Company shall ensure that all DOT testing is conducted only by a laboratory that is certified by the Department of Health and Human Services (HHS) under the National Laboratory Certification Program (NLCP). Doing so ensures that the Company complies with the requirements of Part 40 and with all applicable requirements of HHS in testing DOT specimens, whether or not those requirements are explicitly stated in the Plan. The laboratory used by this Company is specified in Appendix B. The laboratory will report the certified results to the MRO and only to the MRO, at the address provided on the Federal CCF. Results will not be reported directly to the Company or to or through another service agent, such as the C/TPA. Specimen. Urine is the only specimen that is authorized for DOT drug testing. The Company will not use any other specimen (e.g., hair or saliva) for a DOT -required drug test. A "quick test" (e.g,, a urine test that produces an immediate test result) is also prohibited by DOT. Drug Testing. The laboratory will ensure that, on each DOT test, each specimen is tested for marijuana, cocaine, amphetamines, opioids, and phencyclidine (PCP). (See, Table 1) The testing is a "two step" process: all presumptive positive results on the initial test must be confirmed, by a confirmation test. The initial and the confirmation tests use different chemical principles, and separate portions of the original specimen, for test. DOT specimens will not be tested for any other drugs. DOT specimens will not be subjected to DNA testing. Validity Testing. The laboratory will ensure that, on each DOT test, each specimen is also subjected to "validity testing". The purpose of validity testing is to determine if the employee tampered with their specimen during the collection process. Validity testing measures the creatinine concentration and specific gravity to detect a diluted or substituted specimen; ph is measured as one criterion established to detect an adulterated specimen. Validity testing also incorporates HHS criteria (used by DOT) in testing for specific adulterants such as nitrites, chromates, surfactants, and other active chemical compounds. Laboratory Specimen Handling and Reporting. When the laboratory receives a DOT specimen they will unpack and enter it into the testing process. Part of that process is to examine the condition of the specimen bottles and accompanying CCF. The laboratory will look closely for any specific reason to stop the testing process (e.g., "fatal flaws"). If the laboratory determines a fatal flaw exists, the specimen is rejected for testing and the test is cancelled by the MRO. If a fatal flaw does not exist, the specimen will be tested. The following are DOT "fatal flaws": a) There is no CCF; b) Ih cases where a specimen has been collected, there is no specimen submitted with the CCF; c) There is no printed collectors name and no collectors signature; d) Two separate collections are performed using one CCF; e) The specimen ID numbers on the specimen bottle and the CCF do not match; f) The specimen bottle seal is broken or shows evidence of tampering (and a split specimen cannot be re- designated, (see §40.83(h)); and g) Because of leakage or other causes, there is an insufficient amount of urine in the primary specimen bottle for analysis and the specimens cannot be re -designated, (see §40.83(h)). The laboratory will open only the primary specimen (Bottle "A") to conduct the two tests (initial and confirmatory). If the specimen tests negative in either test and does not have any specimen validity issues, the result will be reported to the MRO as negative. Only if the specimen test results are positive, adulterated, substituted, and/or invalid under both tests will the specimen be reported to the MRO as positive, adulterated, substituted, and/or invalid, respectively. These results are also referred to as "non -negative" results. Premium Concrete Services, Inc.- PHMSA DRUG/ALCOHOL PLAN 24 C',NATIONAL COMPLIANCE MANAGEMEM SERVIC[, INC. (NCMS) 2011 (update 2021). Teo NCMS olan'is the subjeG of a raglstereU wVY��9h� and Is protectetl by copyriyhl laws in Ille U.S. and elsevihare. All �igM1ls esMetl